-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$28.008932.26% Upside
FibroGen, Inc. Frequently Asked Questions
-
What analysts cover FibroGen, Inc.?
FibroGen, Inc. has been rated by research analysts at Stifel Nicolaus in the past 90 days.